These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 4991828)

  • 21. The effect of hydergine on the transit time of cerebral circulation in diffuse cerebral insufficiency.
    Mongeau B
    Eur J Clin Pharmacol; 1974; 7(3):169-75. PubMed ID: 4212405
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of an ergot preparation (hydergine) in the convalescent phase of stroke.
    Bochner F; Eadie MJ; Tyrer JH
    J Am Geriatr Soc; 1973 Jan; 21(1):10-7. PubMed ID: 4630036
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical aspects on the therapy of cerebral sclerosis].
    Hoffmeister K
    Med Klin; 1967 Jun; 62(23):910-2. PubMed ID: 4970034
    [No Abstract]   [Full Text] [Related]  

  • 24. Dihydrogenated alkaloids of ergot in geriatric patients: symptomatic treatment of cerebrovascular insufficiency.
    Kaye C
    Bol Asoc Med P R; 1972 Nov; 64(11):301-3. PubMed ID: 4205800
    [No Abstract]   [Full Text] [Related]  

  • 25. [Wallerox increases cerebral circulation and heart capacity].
    Heynen U
    Z Allgemeinmed; 1971 Dec; 47(34):1823-5. PubMed ID: 5003212
    [No Abstract]   [Full Text] [Related]  

  • 26. [Results of treatment with SEN DCS-1. Preliminary note on 24 patients].
    Pastor Franco A
    Rev Clin Esp; 1970 Aug; 118(4):359-64. PubMed ID: 4991986
    [No Abstract]   [Full Text] [Related]  

  • 27. An ergot preparation (hydergine) in the treatment of cerebrovascular disorders in the geriatric patient: double-blind study.
    Ditch M; Kelly FJ; Resnick O
    J Am Geriatr Soc; 1971 Mar; 19(3):208-17. PubMed ID: 4998602
    [No Abstract]   [Full Text] [Related]  

  • 28. [Vergebro-basilar insufficiency. Prevention of transient ischemic accidents with hydergine].
    Augustin P; Lechevalier B
    Therapeutique; 1970 May; 46(5):543-6. PubMed ID: 4988090
    [No Abstract]   [Full Text] [Related]  

  • 29. Chronic cerebrovascular insufficiency in the elderly. Perspectives on treatment.
    Rosen HJ
    J Med Soc N J; 1972 May; 69(5):445-8. PubMed ID: 4623096
    [No Abstract]   [Full Text] [Related]  

  • 30. [Trial of eutergine in chronic cerebral arteriopathies].
    Pauchant M; Bernard JM
    Lille Med; 1972 May; 17():Suppl 4:819-23. PubMed ID: 4626797
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of drugs on cerebrovascular circulation with special regard to Hydergin].
    Radielović P
    Lijec Vjesn; 1971; 93(11):1227-32. PubMed ID: 5005614
    [No Abstract]   [Full Text] [Related]  

  • 32. [Determinants estimating cerebral functions after long term therapy with hydergin].
    Herzfeld U; Christian W; Ronge J; Wittgen M
    Arztl Forsch; 1972 Jun; 26(6):215-28. PubMed ID: 4626216
    [No Abstract]   [Full Text] [Related]  

  • 33. [Sympatholytic vasodilator in cerebral circulation disorders].
    Lipke PR
    Hospital (Rio J); 1969 Dec; 76(6):2159-65. PubMed ID: 4984915
    [No Abstract]   [Full Text] [Related]  

  • 34. [Attempt at psychometric evaluation of aging: study of a vascular drug].
    Losson M; Losson JP
    Therapeutique; 1969 Mar; 45(3):313-7. PubMed ID: 4989246
    [No Abstract]   [Full Text] [Related]  

  • 35. [Study of the association of raubasine and dihydroergocristine in the aged patient with vascular disease].
    Sauter R
    Lille Med; 1971; 17():Suppl 3:551-8. PubMed ID: 5005074
    [No Abstract]   [Full Text] [Related]  

  • 36. An ergot alkaloid preparation (Hydergine) versus papaverine in treating common complaints of the aged: double-blind study.
    Bazo AJ
    J Am Geriatr Soc; 1973 Feb; 21(2):63-71. PubMed ID: 4631704
    [No Abstract]   [Full Text] [Related]  

  • 37. [Trial of a new central and peripheral vaso-regulator therapeutic agent: DF 69].
    Laveant-Hebrard C; Camus JP
    Therapeutique; 1970 Oct; 46(8):805-6. PubMed ID: 4989868
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of cerebral vascular diseases due to softening].
    Tomaselli R; Elia C
    Omnia Med Ther; 1968; 46(3):657-70. PubMed ID: 4989937
    [No Abstract]   [Full Text] [Related]  

  • 39. [Mental effects of Wallerox therapy in the aged].
    Thomae H
    Med Klin; 1970 Jun; 65(23):1132-4. PubMed ID: 5000216
    [No Abstract]   [Full Text] [Related]  

  • 40. [Observations during ambulatory therapy of functional and organic circulatory disorders with Defluina].
    Brüning G
    Med Welt; 1975 Sep; 26(38):1737-41. PubMed ID: 810634
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.